cabozantinib
exelixis
['urothelial carcinoma', 'urothelial', 'cabozantinib', 'blcsm']
in a phase 2 clinical trial, the use of maintenance #cabozantinib following chemotherapy in patients with advanced urothelial carcinoma demonstrated tolerability but did not show a significant benefit vs placebo. #uc #blcsm #asco22 
Oncology news and insights from leading researchers and cancer centers.